Innate Pharma and Novo Nordisk A/S Partnership Refocused on the Inflammatory Field
MARSEILLES, France, Jan. 31, 2008–Innate
Pharma SA (Euronext Paris: FR0010331421 - IPH), the
biopharmaceutical company developing first-in-class drugs targeting
the innate immune system, announces that its partnership with Novo
Nordisk…
Novo Nordisk: Financial statement for 2007
COPENHAGEN, Jan. 31,
2008-Novo Nordisk increased net profit by 32% in 2007. Underlying
operating profit increased by close to 25% primarily driven by a
13% sales growth in local…
Novo Nordisk: Financial statement for 2007
COPENHAGEN, Jan. 31,
2008-Novo Nordisk increased net profit by 32% in 2007. Underlying
operating profit increased by close to 25% primarily driven by a
13% sales growth in local…
AstraZeneca PLC, Fourth Quarter and Full Year Results 2007
LONDON, Jan. 31, 2008– David Brennan, Chief Executive Officer,
said: “The strong underlying results for the full year
reflect our determined action in three priority areas: our pipeline
is significantly stronger, with the acquisition of…
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin Sales and Applications Seeking Two Product Approvals in 2009
2008 Projected Financial Highlights and Potential Milestones include:
- Grow Zevalin sales
- XYOTAX(TM) Marketing Authorization Application submission in Q1
- Pixantrone phase III results and New Drug Application…
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin Sales and Applications Seeking Two Product Approvals in 2009
2008 Projected Financial Highlights and Potential Milestones include:
- Grow Zevalin sales
- XYOTAX(TM) Marketing Authorization Application submission in Q1
- Pixantrone phase III results and New Drug Application…
PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company
TARRYTOWN, N.Y.–(BUSINESS WIRE)–Jan 31, 2008 - PsychoGenics Inc.
today announced that it has entered into an additional drug
discovery agreement with Eli Lilly and Company (NYSE:LLY). Per the
agreement, Lilly will supply pre-candidate compounds…
PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company
TARRYTOWN, N.Y.–(BUSINESS WIRE)–Jan 31, 2008 - PsychoGenics Inc.
today announced that it has entered into an additional drug
discovery agreement with Eli Lilly and Company (NYSE:LLY). Per the
agreement, Lilly will supply pre-candidate compounds…
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
– Posts 33% Sales Growth from Continuing Operations in the Fourth
Quarter 2007
NEW YORK, Jan. 31 /PRNewswire-FirstCall/ — Bristol-Myers Squibb
Company today reported financial results for the fourth quarter and
twelve months ended December 31,…
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
– Posts 33% Sales Growth from Continuing Operations in the Fourth
Quarter 2007
NEW YORK, Jan. 31 /PRNewswire-FirstCall/ — Bristol-Myers Squibb
Company today reported financial results for the fourth quarter and
twelve months ended December 31,…